Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination

MLA

Simon Faissner, et al. “Immune Response in Ofatumumab Treated Multiple Sclerosis Patients after SARS-CoV-2 Vaccination.” Frontiers in Immunology, vol. 13, Aug. 2022. EBSCOhost, https://doi.org/10.3389/fimmu.2022.980526.

APA

Simon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, Paulina Trendelenburg, Ulas Ceylan, Jeremias Motte, Clara Bessen, Doris Urlaub, Carsten Watzl, Oliver Overheu, Anke Reinacher-Schick, Kerstin Hellwig, Stephanie Pfaender, Ingo Schmitz, & Ralf Gold. (2022). Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.980526

Chicago

Simon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, Paulina Trendelenburg, Ulas Ceylan, Jeremias Motte, Clara Bessen, et al. 2022. “Immune Response in Ofatumumab Treated Multiple Sclerosis Patients after SARS-CoV-2 Vaccination.” Frontiers in Immunology 13 (August). doi:10.3389/fimmu.2022.980526.